Evidence map›Paper›PMID 21562038›Full record

Trial reportBlood2011

Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Yousif Matloub, Bruce C Bostrom, Stephen P Hunger, Linda C Stork, Anne Angiolillo, Harland Sather, Mei La, Julie M Gastier-Foster, Nyla A Heerema, Scott Sailer and 9 more

Registry-linked trialAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00005945 (Escalating Dose Intravenous Methotrexate Without Leucovorin Rescue Versus Oral Methotrexate and Single Versus Double Delayed Intensification for Children With Standard Risk Acute Lymphoblastic Leukemia), which is not on this map. Cited by 67 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00005945 phase3completednot on this map

Escalating Dose Intravenous Methotrexate Without Leucovorin Rescue Versus Oral Methotrexate and Single Versus Double Delayed Intensification for Children With Standard Risk Acute Lymphoblastic Leukemia

TypeinterventionalSponsorChildren's Oncology GroupRan2000 to 2008Enrolled3,054ConditionsLeukemiaArmscyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, doxorubicin hydrochloride
3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Yousif MatloubDivision of Hematology-Oncology, Rainbow Babies & Children's Hospital, Case Western Reserve University, Cleveland, OH 44106, USA. yousif.matloub@uhhospitals.org
Bruce C Bostrom
Stephen P Hunger
Linda C Stork
Anne Angiolillo
Harland Sather
Mei La
Julie M Gastier-Foster
Nyla A Heerema
Scott Sailer
Patrick J Buckley
Blythe Thomson
Catherine Cole
James B Nachman
Gregory Reaman
Naomi Winick
William L Carroll
Meenakshi Devidas
Paul S Gaynon

Funding

COG FOREIGN ACCRUALU10CA098543 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ADAMSON, PETER C. · 2003 to 2013
$335.5M
Children's Oncology Group Statistics &Data Center GrantU10CA098413 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI DEVIDAS, MEENAKSHI · 2003 to 2013
$67.5M
CHILDRENS CANCER STUDY GROUP CHAIRMAN'S GRANTU10CA013539 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI REAMAN, GREGORY H · 1985 to 2002
$43.1M
NCI NIH HHS CA-13539NCI NIH HHS CA-98413NCI NIH HHS CA-98543NCI NIH HHS U10 CA098413NCI NIH HHS U10 CA098543
6 · The paper itself

Abstract

Children's Cancer Group-1991 selected 2 components from the Children's Cancer Group studies shown to be effective in high-risk acute lymphoblastic leukemia and examined them in children with National Cancer Institute standard-risk acute B-precursor lymphoblastic leukemia. These were (1) vincristine and escalating IV methotrexate (MTX) without leucovorin rescue during the interim maintenance (IM) phases and (2) addition of a second delayed intensification (DI) phase. Eligible patients (n = 2078) were randomly assigned to regimens containing either oral (PO) MTX, PO mercaptopurine, dexamethasone, and vincristine or IV MTX during IM phases, and regimens with either single DI or double DI. Five-year event-free survival (EFS) and overall survival for patients on the PO MTX arms were 88.7% ± 1.4% and 96% ± 0.9% versus 92.6% ± 1.2% and 96.5% ± 0.8% for those on the IV MTX arms (P = .009, P = .66). Five-year EFS and overall survival for patients who received single DI were 90.9% ± 1.3% and 97.1% ± 0.8% versus 90.5% ± 1.3% and 95.4% ± 3.8% for those who received double DI (P = .71, P = .12). No advantage was found for a second DI; however, replacement of PO MTX, PO mercaptopurine, vincristine, and dexamethasone during IM with vincristine and escalating IV MTX improved EFS.

Indexed as

AlgorithmsAntineoplastic AgentsChildChild, PreschoolDisease-Free SurvivalDose-Response Relationship, DrugFemaleHumansInfantInjections, IntravenousMaleMedical OncologyMethotrexateNeoplasm StagingPrecursor Cell Lymphoblastic Leukemia-LymphomaRiskAntineoplastic AgentsMethotrexate

Identifiers

PMID21562038
PMCPMC3138679

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.